Table 1. Open in new tab Baseline...

Dialysis patients (n = 7566)^a

Transplanted patients (n = 1504)^a

Danish background population 2000 (n = 4 091 776)

P-value^b

Age, years (IQR) (range)

69 (60–76)* (19–95)

49 (38–58) (18–76)

46 (33–60) (18–110)

<0.0001*

Women

2791 (36.9)*

580 (38.6)*

2 095 958 (51.2)

<0.0001

Time on dialysis

0 (0–0)*

1.7 (0.6–3.4)*

<0.0001*

Prior fracture 5 years before

967 (12.8)*

162 (10.8)**

365 794 (8.9)

<0.0001***

Charlson Comorbidity Index

2 (0–3)*

0 (0–2)*

0 (0–0)

<0.0001*

Comorbidity for each parameter in Charlson score

Myocardial infarction

776 (10.3)*

46 (3.1)*

36 366 (0.9)

<0.0001*

Congestive heart failure

1488 (19.7)*

85 (5.7)*

39 977 (1.0)

<0.0001*

Peripheral vascular disease

1324 (17.5)*

85 (5.7)*

36 216 (0.9)

<0.0001*

Cerebrovascular disease

377 (5.0)*

29 (1.9)*

23 391 (0.6)

<0.0001*

Dementia

5 (0.1)

0 (0.54)

1038 (<0.1)

0.07

Chronic pulmonary disease

713 (9.4)*

26 (1.7)

48 635 (1.2)

<0.0001*

Rheumatic disease

240 (3.2)*

24 (1.6)*

23 798 (0.6)

<0.0001**

Peptic ulcer disease

865 (11.4)*

126 (8.4)*

72 674 (1.8)

<0.0001**

Mild liver disease

185 (2.5)*

24 (1.6)*

12 976 (0.3)

<0.0001

Diabetes without chronic complications

199 (2.6)*

34 (2.3)*

34 014 (0.8)

<0.0001

Diabetes with chronic complications

2274 (30.1)*

288 (19.2)*

29 887 (0.7)

<0.0001*

Hemi- or paraplegia

33 (0.4)*

4 (0.3)**

3179 (0.1)

<0.0001

Moderate to severe chronic kidney disease

7566 (100)*

1504 (100)*

3096 (0.1)

<0.0001

Solid malignant tumours

872 (11.5)*

47 (3.1)**

91 596 (2.2)

<0.0001*

Leukaemia

30 (0.4)*

1 (0.1)

3029 (0.1)

<0.0001

Lymphoma

245 (3.2)*

6 (0.4)**

5903 (0.1)

<0.0001*

Moderate or severe liver disease

13 (0.2)*

4 (0.3)*

486 (<0.1)

<0.0001

Metastatic solid tumour

35 (0.5)*

3 (0.2)

2791 (0.1)

<0.0001

AIDS/HIV

14 (0.2)*

3 (0.2)**

1873 (0.1)

<0.0001

Medication

Vitamin K antagonists

646 (8.5)*

67 (4.5)*

30 568 (0.8)

<0.0001*

Aspirin

2737 (36.2)*

227 (15.1)*

192 531 (4.7)

<0.0001*

Clopidogrel

268 (3.5)*

14 (0.9)*

1278 (<0.1)

<0.0001*

Proton pump inhibitors

2446 (32.3)*

503 (33.4)*

114 787 (2.8)

<0.0001

Diuretics

5483 (72.5)*

904 (60.1)*

348 831 (8.5)

<0.0001*

β blockers

3390 (44.8)*

766 (50.9)*

167 958 (4.1)

<0.0001*

Calcium antagonists

3977 (52.6)*

790 (52.5)*

167 244 (4.1)

<0.0001

Inhibitors of the renin–angiotensin system

3457 (46.0)*

964 (64.1)*

183 876 (4.5)

<0.0001*

Digoxin

561 (7.4)*

21 (1.4)

61 086 (1.5)

<0.0001*

Antiarrhythmic class I and III

105 (1.4)*

4 (0.3)

6637 (0.2)

<0.0001*

Bisphosphonates

74 (1.0)*

4 (0.2)

14 476 (0.4)

<0.0001***

Lipid-modifying agents

2146 (28.4)*

3523 (23.4)*

64 583 (1.6)

<0.0001*

Dialysis patients (n = 7566)^a

Transplanted patients (n = 1504)^a

Danish background population 2000 (n = 4 091 776)

P-value^b

Age, years (IQR) (range)

69 (60–76)* (19–95)

49 (38–58) (18–76)

46 (33–60) (18–110)

<0.0001*

Women

2791 (36.9)*

580 (38.6)*

2 095 958 (51.2)

<0.0001

Time on dialysis

0 (0–0)*

1.7 (0.6–3.4)*

<0.0001*

Prior fracture 5 years before

967 (12.8)*

162 (10.8)**

365 794 (8.9)

<0.0001***

Charlson Comorbidity Index

2 (0–3)*

0 (0–2)*

0 (0–0)

<0.0001*

Comorbidity for each parameter in Charlson score

Myocardial infarction

776 (10.3)*

46 (3.1)*

36 366 (0.9)

<0.0001*

Congestive heart failure

1488 (19.7)*

85 (5.7)*

39 977 (1.0)

<0.0001*

Peripheral vascular disease

1324 (17.5)*

85 (5.7)*

36 216 (0.9)

<0.0001*

Cerebrovascular disease

377 (5.0)*

29 (1.9)*

23 391 (0.6)

<0.0001*

Dementia

5 (0.1)

0 (0.54)

1038 (<0.1)

0.07

Chronic pulmonary disease

713 (9.4)*

26 (1.7)

48 635 (1.2)

<0.0001*

Rheumatic disease

240 (3.2)*

24 (1.6)*

23 798 (0.6)

<0.0001**

Peptic ulcer disease

865 (11.4)*

126 (8.4)*

72 674 (1.8)

<0.0001**

Mild liver disease

185 (2.5)*

24 (1.6)*

12 976 (0.3)

<0.0001

Diabetes without chronic complications

199 (2.6)*

34 (2.3)*

34 014 (0.8)

<0.0001

Diabetes with chronic complications

2274 (30.1)*

288 (19.2)*

29 887 (0.7)

<0.0001*

Hemi- or paraplegia

33 (0.4)*

4 (0.3)**

3179 (0.1)

<0.0001

Moderate to severe chronic kidney disease

7566 (100)*

1504 (100)*

3096 (0.1)

<0.0001

Solid malignant tumours

872 (11.5)*

47 (3.1)**

91 596 (2.2)

<0.0001*

Leukaemia

30 (0.4)*

1 (0.1)

3029 (0.1)

<0.0001

Lymphoma

245 (3.2)*

6 (0.4)**

5903 (0.1)

<0.0001*

Moderate or severe liver disease

13 (0.2)*

4 (0.3)*

486 (<0.1)

<0.0001

Metastatic solid tumour

35 (0.5)*

3 (0.2)

2791 (0.1)

<0.0001

AIDS/HIV

14 (0.2)*

3 (0.2)**

1873 (0.1)

<0.0001

Medication

Vitamin K antagonists

646 (8.5)*

67 (4.5)*

30 568 (0.8)

<0.0001*

Aspirin

2737 (36.2)*

227 (15.1)*

192 531 (4.7)

<0.0001*

Clopidogrel

268 (3.5)*

14 (0.9)*

1278 (<0.1)

<0.0001*

Proton pump inhibitors

2446 (32.3)*

503 (33.4)*

114 787 (2.8)

<0.0001

Diuretics

5483 (72.5)*

904 (60.1)*

348 831 (8.5)

<0.0001*

β blockers

3390 (44.8)*

766 (50.9)*

167 958 (4.1)

<0.0001*

Calcium antagonists

3977 (52.6)*

790 (52.5)*

167 244 (4.1)

<0.0001

Inhibitors of the renin–angiotensin system

3457 (46.0)*

964 (64.1)*

183 876 (4.5)

<0.0001*

Digoxin

561 (7.4)*

21 (1.4)

61 086 (1.5)

<0.0001*

Antiarrhythmic class I and III

105 (1.4)*

4 (0.3)

6637 (0.2)

<0.0001*

Bisphosphonates

74 (1.0)*

4 (0.2)

14 476 (0.4)

<0.0001***

Lipid-modifying agents

2146 (28.4)*

3523 (23.4)*

64 583 (1.6)

<0.0001*

Table 1.

Open in new tab

Baseline characteristics of the patients

	Dialysis patients (n = 7566)^a	Transplanted patients (n = 1504)^a	Danish background population 2000 (n = 4 091 776)	P-value^b
Age, years (IQR) (range)	69 (60–76)* (19–95)	49 (38–58) (18–76)	46 (33–60) (18–110)	<0.0001*
Women	2791 (36.9)*	580 (38.6)*	2 095 958 (51.2)	<0.0001
Time on dialysis	0 (0–0)*	1.7 (0.6–3.4)*	0	<0.0001*
Prior fracture 5 years before	967 (12.8)*	162 (10.8)**	365 794 (8.9)	<0.0001***
Charlson Comorbidity Index	2 (0–3)*	0 (0–2)*	0 (0–0)	<0.0001*
Comorbidity for each parameter in Charlson score
Myocardial infarction	776 (10.3)*	46 (3.1)*	36 366 (0.9)	<0.0001*
Congestive heart failure	1488 (19.7)*	85 (5.7)*	39 977 (1.0)	<0.0001*
Peripheral vascular disease	1324 (17.5)*	85 (5.7)*	36 216 (0.9)	<0.0001*
Cerebrovascular disease	377 (5.0)*	29 (1.9)*	23 391 (0.6)	<0.0001*
Dementia	5 (0.1)	0 (0.54)	1038 (<0.1)	0.07
Chronic pulmonary disease	713 (9.4)*	26 (1.7)	48 635 (1.2)	<0.0001*
Rheumatic disease	240 (3.2)*	24 (1.6)*	23 798 (0.6)	<0.0001**
Peptic ulcer disease	865 (11.4)*	126 (8.4)*	72 674 (1.8)	<0.0001**
Mild liver disease	185 (2.5)*	24 (1.6)*	12 976 (0.3)	<0.0001
Diabetes without chronic complications	199 (2.6)*	34 (2.3)*	34 014 (0.8)	<0.0001
Diabetes with chronic complications	2274 (30.1)*	288 (19.2)*	29 887 (0.7)	<0.0001*
Hemi- or paraplegia	33 (0.4)*	4 (0.3)**	3179 (0.1)	<0.0001
Moderate to severe chronic kidney disease	7566 (100)*	1504 (100)*	3096 (0.1)	<0.0001
Solid malignant tumours	872 (11.5)*	47 (3.1)**	91 596 (2.2)	<0.0001*
Leukaemia	30 (0.4)*	1 (0.1)	3029 (0.1)	<0.0001
Lymphoma	245 (3.2)*	6 (0.4)**	5903 (0.1)	<0.0001*
Moderate or severe liver disease	13 (0.2)*	4 (0.3)*	486 (<0.1)	<0.0001
Metastatic solid tumour	35 (0.5)*	3 (0.2)	2791 (0.1)	<0.0001
AIDS/HIV	14 (0.2)*	3 (0.2)**	1873 (0.1)	<0.0001
Medication
Vitamin K antagonists	646 (8.5)*	67 (4.5)*	30 568 (0.8)	<0.0001*
Aspirin	2737 (36.2)*	227 (15.1)*	192 531 (4.7)	<0.0001*
Clopidogrel	268 (3.5)*	14 (0.9)*	1278 (<0.1)	<0.0001*
Proton pump inhibitors	2446 (32.3)*	503 (33.4)*	114 787 (2.8)	<0.0001
Diuretics	5483 (72.5)*	904 (60.1)*	348 831 (8.5)	<0.0001*
β blockers	3390 (44.8)*	766 (50.9)*	167 958 (4.1)	<0.0001*
Calcium antagonists	3977 (52.6)*	790 (52.5)*	167 244 (4.1)	<0.0001
Inhibitors of the renin–angiotensin system	3457 (46.0)*	964 (64.1)*	183 876 (4.5)	<0.0001*
Digoxin	561 (7.4)*	21 (1.4)	61 086 (1.5)	<0.0001*
Antiarrhythmic class I and III	105 (1.4)*	4 (0.3)	6637 (0.2)	<0.0001*
Bisphosphonates	74 (1.0)*	4 (0.2)	14 476 (0.4)	<0.0001***
Lipid-modifying agents	2146 (28.4)*	3523 (23.4)*	64 583 (1.6)	<0.0001*

	Dialysis patients (n = 7566)^a	Transplanted patients (n = 1504)^a	Danish background population 2000 (n = 4 091 776)	P-value^b
Age, years (IQR) (range)	69 (60–76)* (19–95)	49 (38–58) (18–76)	46 (33–60) (18–110)	<0.0001*
Women	2791 (36.9)*	580 (38.6)*	2 095 958 (51.2)	<0.0001
Time on dialysis	0 (0–0)*	1.7 (0.6–3.4)*	0	<0.0001*
Prior fracture 5 years before	967 (12.8)*	162 (10.8)**	365 794 (8.9)	<0.0001***
Charlson Comorbidity Index	2 (0–3)*	0 (0–2)*	0 (0–0)	<0.0001*
Comorbidity for each parameter in Charlson score
Myocardial infarction	776 (10.3)*	46 (3.1)*	36 366 (0.9)	<0.0001*
Congestive heart failure	1488 (19.7)*	85 (5.7)*	39 977 (1.0)	<0.0001*
Peripheral vascular disease	1324 (17.5)*	85 (5.7)*	36 216 (0.9)	<0.0001*
Cerebrovascular disease	377 (5.0)*	29 (1.9)*	23 391 (0.6)	<0.0001*
Dementia	5 (0.1)	0 (0.54)	1038 (<0.1)	0.07
Chronic pulmonary disease	713 (9.4)*	26 (1.7)	48 635 (1.2)	<0.0001*
Rheumatic disease	240 (3.2)*	24 (1.6)*	23 798 (0.6)	<0.0001**
Peptic ulcer disease	865 (11.4)*	126 (8.4)*	72 674 (1.8)	<0.0001**
Mild liver disease	185 (2.5)*	24 (1.6)*	12 976 (0.3)	<0.0001
Diabetes without chronic complications	199 (2.6)*	34 (2.3)*	34 014 (0.8)	<0.0001
Diabetes with chronic complications	2274 (30.1)*	288 (19.2)*	29 887 (0.7)	<0.0001*
Hemi- or paraplegia	33 (0.4)*	4 (0.3)**	3179 (0.1)	<0.0001
Moderate to severe chronic kidney disease	7566 (100)*	1504 (100)*	3096 (0.1)	<0.0001
Solid malignant tumours	872 (11.5)*	47 (3.1)**	91 596 (2.2)	<0.0001*
Leukaemia	30 (0.4)*	1 (0.1)	3029 (0.1)	<0.0001
Lymphoma	245 (3.2)*	6 (0.4)**	5903 (0.1)	<0.0001*
Moderate or severe liver disease	13 (0.2)*	4 (0.3)*	486 (<0.1)	<0.0001
Metastatic solid tumour	35 (0.5)*	3 (0.2)	2791 (0.1)	<0.0001
AIDS/HIV	14 (0.2)*	3 (0.2)**	1873 (0.1)	<0.0001
Medication
Vitamin K antagonists	646 (8.5)*	67 (4.5)*	30 568 (0.8)	<0.0001*
Aspirin	2737 (36.2)*	227 (15.1)*	192 531 (4.7)	<0.0001*
Clopidogrel	268 (3.5)*	14 (0.9)*	1278 (<0.1)	<0.0001*
Proton pump inhibitors	2446 (32.3)*	503 (33.4)*	114 787 (2.8)	<0.0001
Diuretics	5483 (72.5)*	904 (60.1)*	348 831 (8.5)	<0.0001*
β blockers	3390 (44.8)*	766 (50.9)*	167 958 (4.1)	<0.0001*
Calcium antagonists	3977 (52.6)*	790 (52.5)*	167 244 (4.1)	<0.0001
Inhibitors of the renin–angiotensin system	3457 (46.0)*	964 (64.1)*	183 876 (4.5)	<0.0001*
Digoxin	561 (7.4)*	21 (1.4)	61 086 (1.5)	<0.0001*
Antiarrhythmic class I and III	105 (1.4)*	4 (0.3)	6637 (0.2)	<0.0001*
Bisphosphonates	74 (1.0)*	4 (0.2)	14 476 (0.4)	<0.0001***
Lipid-modifying agents	2146 (28.4)*	3523 (23.4)*	64 583 (1.6)	<0.0001*

Baseline characteristics for dialysis patients, patients with renal transplants and the Danish background population year 2000. Data are presented as numbers (%) or medians (IQR). P-value for overall test for differences between groups.

^aPost hoc analysis of baseline characteristics between groups: *P < 0.0001 or **P < 0.05 in treated group versus Danish background population.

^bP-values: *P < 0.0001, **P < 0.001 or ***P < 0.05 in dialysis versus renal transplanted patients.

This Feature Is Available To Subscribers Only